Oon Han Hee, Kim Seung Hae, Kim Kyoung-Hee, Hur Gwong-Cheung, Joo Yim Hyeon, Chung Hee-Kyung, Ho Woo Sung, Dong Koo Ki, Lee Chang-Seok, Sung Koh Jong, Kim Geun Tae
Research and Development, LG Life Sciences, 104-1 Munji-dong, Yuseong-gu, Daejon 305-380, Republic of Korea.
Bioorg Med Chem Lett. 2007 Feb 15;17(4):937-41. doi: 10.1016/j.bmcl.2006.11.050. Epub 2006 Nov 18.
Oxime ethers of alpha-acyl-beta-phenylpropanoic acids were prepared to apply as PPARalpha and gamma dual agonists. Among them, compound 11l proved to exhibit potent in vitro activities with EC(50) of 19 and 13nM in PPARalpha and gamma, respectively. It showed better glucose lowering effects than rosiglitazone 1 and ameliorated the lipid profile like plasma triglyceride in db/db mice model.
制备了α-酰基-β-苯基丙酸的肟醚,用作过氧化物酶体增殖物激活受体α(PPARα)和γ(PPARγ)双重激动剂。其中,化合物11l在体外表现出强效活性,在PPARα和PPARγ中的半数有效浓度(EC50)分别为19 nM和13 nM。在db/db小鼠模型中,它显示出比罗格列酮1更好的降血糖效果,并改善了脂质状况,如血浆甘油三酯。